time, but whether similar shifts also occur after clinical diagnosis and insulin treatment in T1D patients is unknown.
RESEARCH DESIGN AND METHODS-We took advantage of a recently validated islet-specific CD8
+ T-cell IFN-γ enzyme-linked immunospot (ISL8Spot) assay to follow responses against preproinsulin (PPI), GAD, IA-2 and islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP) epitopes in 15 HLA-A2 + adult T1D patients close to diagnosis and at a second time point 7-16 months after.
RESULTS-CD8
+ T-cell reactivities were less frequent at follow-up, as 28.6% of responses tested positive at T1D diagnosis vs. 13.2% after a median of 11 months (P=0.003). While GAD and IA-2 autoantibody (aAb) titers were unchanged in 75% of cases, the fraction of patients responding to PPI and/or GAD epitopes by ISL8Spot diabetes (T1D) in the NOD mouse (1, 2) . Three different CD8 + pathogenic clones specific for proinsulin (PI) B15-23 (3) , islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP) [206] [207] [208] [209] [210] [211] [212] [213] [214] (4) and dystrophia myotonica kinase (DMK) [138] [139] [140] [141] [142] [143] [144] [145] [146] (5) have been described. These specificities are highly immunodominant in NOD mice, as T-cells recognizing them are abundantly present in the early insulitis infiltrates (6, 7) . Moreover, the rise in circulating IGRP 206-214 -specific CD8 + T-cells can predict impending T1D onset in NOD mice (8) .
More recent data suggest that there could be a hierarchy of spreading from one reactivity to another, as NOD mice made tolerant to PI are protected from diabetes and do not develop IGRP-specific CD8 + responses, while IGRP-tolerant mice still become diabetic and mount PI-specific responses (9) . The initiating role of PI is further supported by the fact that PI knockout mice reconstituted with a hormonally active PI transgene carrying a single tyrosine to alanine mutation at position B16 are completely protected from T1D (10, 11) . This substitution affects both the PI B15-23 epitope and an overlapping immunodominant PI B9-23 CD4 + epitope (12, 13) .
Mirroring these mouse data, CD8 + T-cells have recently received increasing attention also for human T1D (14) (15) (16) (17) (18) (19) , as their detection could provide new autoimmune markers of β-cell aggression. Development of such markers is important to complement autoantibody (aAb) readouts. Indeed, aAbs can separate T1D from healthy subjects with high sensitivity and specificity, making them indispensable tools for diagnostic classification and T1D prediction. However, the utility of aAbs for immune monitoring purposes is limited by the fact that they do not reflect tolerance restoration following therapeutic manipulation (20, 21) .
To be clinically applicable, T-cell assays should be developed that can be easily transferred into routine laboratory testing. The first validation step for such assays is to test their diagnostic sensitivity and specificity in separating T1D from healthy subjects. For CD4 + T-cells, the cellular immunoblotting technique of was the assay showing the best performance (23). In many other instances, β-cell-specific CD4 + T-cells were detected in all individuals irrespective of disease status (24,25), although probably characterized by different phenotypes (26-28).
For CD8 + T-cells, we have recently proposed an islet-specific CD8 + T-cell IFN-γ ELISpot (ISL8Spot) assay (18, 29) . The ISL8Spot employs HLA-A2-restricted β-cell epitopes derived from pre-PI (PPI) (30) , GAD, insulinoma-associated protein 2 (IA-2) (17) and IGRP (31), which have been mostly identified by proteasome digestion and DNA immunization strategies (32). Using a single IFN-γ secretion readout on unfractionated PBMCs, this assay detects and quantifies β-cell-reactive CD8 + T-cells directly ex vivo (18) . Beta-cell epitope-specific CD8 + T-cells were thus found at an average frequency of 0.008%, ranging from 0.0008 to 0.08% of total PBMCs. The presence vs. absence of these cells allowed discrimination of T1D vs. healthy subjects with high sensitivity and specificity (18) .
The natural history of CD8 + T-cell responses after T1D clinical onset and start of insulin treatment has not been explored. We know from the NOD mouse that the PI B15-23 -specific fraction is highly immunodominant already at 5 wk (i.e., in the pre-6 diabetic period), but rapidly disappears, becoming negligible by 20 wk (i.e., after T1D onset). In parallel, the IGRP 206-214 -specific fraction increases in number, while undergoing an avidity maturation process which selects the clonotypes of higher avidity (6, 8) . Whether similar shifts in epitope targeting also apply to human T1D is unknown. We therefore used the ISL8Spot assay to measure CD8 + T-cell responses against different β-cell epitopes at T1D clinical onset and after some months of follow-up. Our results reveal a fast waning of most ISL8Spot responses, which contrasts with the steady titers of GAD and IA-2 aAbs. Few new T-cell reactivities appear, which focus on previously subdominant IA-2 and IGRP epitopes.
Research design and methods
Peptides. The HLA-A2-restricted β-cell epitopes used (Tab. 1) were previously described (17, 18, 31) . A viral peptide pool of Flu MP 58-66 (GILGFVFTL), EpsteinBarr virus BMLF 280-288 (GLCTLVAML) and cytomegalovirus pp65 [495] [496] [497] [498] [499] [500] [501] [502] [503] (NLVPMVATV) and phytohemagglutinin (PHA, 1 µg/ml; Sigma, Lyon, France)
were used as positive controls. HIV gag [77] [78] [79] [80] [81] [82] [83] [84] [85] (SLYNTVATL) and DMSO diluent were included as negative controls. All peptides were used at 10 µM and were >80% pure (Schafer-N, Copenhagen, Denmark). Responses against these 9-to 10-amino acidlong epitopes originate from CD8 + T-cells, as previously shown (18). Available subjects wishing to continue the study were subsequently drawn and tested a second time under identical conditions. All subjects gave informed consent and the study was approved by the relevant Ethics Committees.
Blood processing. All blood samples were shipped overnight at room temperature.
Rapid HLA-A2 screening was performed with the BB7.2 mAb, followed by subtyping using the Olerup SSP HLA*02 kit (GenoVision/Qiagen, Vienna, Austria)
to verify the presence of the HLA-A*0201 allele (>95% of HLA-A2 + individuals).
PBMCs were isolated by density gradient centrifugation using lymphocyte separation The cut-off for a positive response was set at 3SD above the average basal reactivity (i.e., reactivity against HIV gag 77-85 and DMSO diluent alone). This was chosen as the cut-off allowing for the best diagnostic sensitivity (i.e., highest number of positive responses to β-cell epitopes in T1D patients) and specificity (i.e., lowest number of positive responses in healthy controls), as determined by receiver-operator characteristics analysis (18) . 
T-cell clone dilution experiments.

Results
Assay validation
The reproducibility of our ELISpot technique has been previously reported (18) .
Variability was found to be of 14.1% intra-assay, 4.2% at the analytical inter-assay level (i.e., using thawed PBMC samples frozen on the same occasion) and 9.2% at the pre-analytical and analytical level (i.e., using separate blood draws from the same donor). One further problem that is encountered in a longitudinal setting is that the basal reactivity level (i.e., spontaneous IFN-γ production in the absence of stimuli) Figure 1 , background levels more than 10-fold different (7.3, 21.7 and 85.5 SFC/10 6 PBMCs, respectively) did not significantly affect the detection sensitivity of the system (i.e., the basal-subtracted net signal) over a wide range of frequencies.
Moreover, all counts were above the basal + 3SD positive cut-off value calculated from the respective backgrounds.
Most CD8 + T-cell responses are short-lived after T1D onset
We considered β-cell epitopes that we previously defined as targets of CD8 + T-cells in 19-50% of adult new-onset T1D patients, but not of age-matched healthy controls (17, 18) . These epitopes were derived from four different β-cell Ags, namely PPI, GAD, IA-2 and IGRP. A complete list is presented in Table 1 .
Fifteen new-onset T1D patients were available for follow-up within a median of 11 months (range 7-16; Tab. 2). Their mean age at diagnosis was of 27.6±8.4 years and their median T1D duration at the time of the first blood draw was of 13 days (range 2-180). Fifteen age-matched healthy controls (mean age 28.8±5.9) were also tested twice, within a median follow-up period of 14 months (range [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] .
Results expressed as number of SFC/10 6 PBMCs, are summarized in Figure 2 . All healthy control subjects were negative at follow-up, including two individuals (i.e., Those patients with detectable reactivities could be divided in two categories: on one side, patients already positive at diagnosis (i.e., patients P04, P09, P10, P11, P14 and P15), in whom at least one of the original epitopes was still recognized, while new ones sometimes emerged (i.e., P04, P11, P14). On the other side, patients whose responses were all negative at diagnosis and who developed scattered reactivities at follow-up (1-2 epitopes recognized; patients P06 and P08). CD8 + T-cell responses against a pool of viral epitopes were included as internal controls. They decreased or disappeared only in 2 patients (P08 and P11), remaining unchanged in all other instances (13/15; 87%) . Of the total positive T-cell responses to islet epitopes observed at diagnosis, the majority (26/42; 62%) dropped to non-detectable levels, while few of them (8/42; 19% ) remained detectable at follow-up. Only in 5 patients (i.e., P04, P06, P08, P11
and P14) did new epitopes become targeted (8/42; 19%) . Except for patient P04 who recognized PI B18-27 , in all other instances (7/8; 87.5%) the newly targeted epitopes were IA-2 206-214 and IGRP [265] [266] [267] [268] [269] [270] [271] [272] [273] . These two epitopes were recognized together in 3 of 4 patients.
While the number of patients responding to epitopes derived from PPI and GAD significantly decreased (60% to 20% for PPI; 67% to 20% for GAD; P<0.02; Second in order came IGRP 265-273 , which was recognized by 27% (3/11) of patients ( Fig. 4B) , thus constituting 19% (3/16) of all reactivities detected (Fig. 5) . Another 20% of patients and 19% of reactivities were covered at follow-up by GAD 114-123 and PI B18-27 , which were the two immunodominant epitopes at diagnosis (53% and 36%
prevalence and 23% and 14% relative frequency, respectively (Fig. 4B and Fig. 5 ) where, besides GAD 114-123 and PI B18-27 emerging as the immunodominant specificities, the other 7 epitopes were evenly ranked (13-29% prevalence, 6-12% of total reactivities).
aAb titers remain stable in face of fading CD8 + T-cell responses.
A sharp dichotomy was observed when comparing the progression of aAb titers and The picture was different when we compared (a)Ab and T-cell responses against PPI.
In line with their adult onset T1D, all but two (13/15; 86.7%) patients were negative for IAA at diagnosis (Tab. 2). Following initiation of insulin therapy, insulin Ab titers became positive in most patients, with the exception of P03 and P10. P10 was also one of the three patients for whom PI-specific T-cell responses were still detectable at follow-up.
Discussion
We here describe the progression of β-cell-directed CD8 + T-cell responses after T1D
clinical onset and initiation of insulin therapy. As the aim of this study was the longitudinal evaluation of T1D patients rather than their comparison with healthy controls, the fact that these two groups were matched only with respect to age does not bias our conclusions. In this longitudinal setting, it is instead essential to distinguish between changes in T-cell responses due to the variability of the ISL8Spot technique from those reflecting true biological fluctuations. In this respect, the 9.2%
inter-assay variability registered when analyzing separate blood draws from the same individual (18) There are several hypotheses which, without being mutually exclusive, could explain the rapid disappearance of most β-cell specific IFN-γ-producing CD8 + T-cells after T1D diagnosis. The simplest explanation is that these T-cells are no longer detected just because they are no longer present at sufficient frequencies. They may have been deleted or suppressed as part of the natural blunting of (auto)immune responses.
Although some β-cells are thought to survive for a long time after T1D onset, the increasing paucity of islet Ags may doom most of these T-cells to die for lack of Ag A third explanation is that the epitope specificity of the CD8 + T-cell population may have shifted towards different targets. Although it is possible that other unknown specificities become prevalent, an epitope focusing phenomenon was observed.
Indeed, only six of the nine original epitopes were still targeted at follow-up. While the decreasing PI-specific responses and the increasing of IGRP 265-273 reactivity are reminiscent of NOD mouse data (6), the finding of a similar phenomenon for GAD and IA-2 is unparalleled. This is not surprising, since GAD and IA-2 are thought to be important target Ags in human T1D (15, 17, 26, (37) (38) (39) , but not in the NOD mouse (40) (41) (42) (43) . Consideration of additional epitopes poorly recognized at T1D onset (17,18) may reveal further specificities becoming immunodominant at later time points. It is also interesting that, similarly to the overlapping PI B9-23 and PI B15-23 mouse epitopes, the immunodominant human CD8 + T-cell epitopes at diagnosis (i.e., of T1D (i.e., 5-year probability to develop disease in at-risk subjects). Conversely, the faster kinetics of T-cell responses may be less useful to predict long-term odds, but better suited to reflect more proximal events, i.e., the "whens" of T1D once disease onset, remission or relapse are approaching.
Another important application for T-cell assays will be for the etiologic classification of borderline cases. One such example is patient P03, whose diagnosis of T1D could be questioned, having ketoacidosis and insulin-dependency at diagnosis but being seronegative and genetically protected (DR15 + with no HLA Class II susceptibility allele). Nonetheless, his robust CD8 + T-cell responses at diagnosis hint an autoimmune component for his diabetes.
The disappearance of most CD8 + T-cell responses following T1D onset and initiation of insulin therapy has also important implications for the application of T-cell assays in the clinics. There is quite some parallelism between human and NOD mouse data, as in both cases T-cell responses significantly wane after clinical onset (8) . If this human/mouse parallel holds true also for the pre-diabetic period, we may find the zenith of T-cell responses before diabetes onset. Longitudinal follow-up of at-risk subjects will shed further light on the time course of these events. For PPI, aa numbering is given both with respect to the PI sequence alone (aa B1-A21) and to the complete PPI sequence (aa 1-110). Prevalence of single epitope specificities in T1D patients at diagnosis and at follow-up. **P<0.05. Figure 5 . Relative distribution of epitope specificities. The percent prevalence of each epitope out of all epitopes recognized at diagnosis (n=34) and at follow-up (n=16) is shown.
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